Alamar Biosciences

Update in progress

ALMR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Alamar Biosciences, Inc. is a proteomics company that develops a proteomic liquid biopsy platform powered by NULISA technology to detect and quantify protein biomarkers. It offers the ARGO high-throughput system, a fully automated platform enabling ultra-high sensitivity, multiplexed analysis from discovery to translational research and diagnostics. Applications include immunology, neurology, and oncology. Based in Fremont, California, founded in 2018. Serves global research institutions, biopharma, CROs, and service labs.

Company score

Sentiment: 0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.21; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.31; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive